We are monitoring the impact of COVID-19 on Europe Biologics Market Get in touch with us for detailed analysis Know More
Pulished Date May, 2021
ID: 11529
Share on
Share on

Europe Biologics Market Research Report – Segmented By Source, Product, Biologics Manufacturing Type, Disease Category & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: May, 2021
ID: 11529
Pages: 100

Europe Biologics Market Size (2021 to 2026)

The size of the European biologics market is forecasted to witness a healthy CAGR during the forecast period.

Biologics, which are used to treat various illnesses and ailments such as anemia, cancer, and autoimmune diseases, is expected to drive the growth of the Europe biologics market. In addition, the market is predicted to develop due to rising demand for innovative therapies, an increase in the prevalence of chronic diseases in this region year on year, and significant changes in people’s social behavior. On the other hand, a greater awareness of disease’s genetic and molecular origins has paved the path for developing several personalized treatments. For example, recombinant proteins help the immune system recognize and bind foreign substances.

Furthermore, rising capital expenditure from key competitors and an expanding population are expected to boost the market expansion. Moreover, the European biologics market is predicted to grow due to strong development efforts and growing markets. Gene-based and cellular biologics, which are utilized to treat various medical conditions, including uncommon disorders, are heavily used in biomedical science. Biologic medications are usually injected into the patient’s body due to their large molecule scale and delicate molecular composition. Therefore, population growth and changes in social behavior are predicted to drive market expansion. In addition, the increased demand for biologics and increasing outstanding by pharmaceutical companies in industrialized countries are driving the Europe biologics market.

Regulatory pricing pressures and a lack of biosimilar expertise among primary care physicians and specialists were two problems that inhibited expansion in the past. In addition, the lack of biologics in low-income nations is projected to restrict industry expansion. On the other hand, the European biologics market is hampered by high costs and a lack of reimbursement.

Impact of COVID-19 on the European Biologics Market:

During the pandemic lockdown, the Europe biologics market was disrupted, and biologics consumer devices and prescription drug production were delayed. Due to the strict COVID-19 rules, no biologics drugs have been extracted during the first quarter of 2020. The rising COVID-19 burden has generated an enormous demand for biologics during the pandemic, propelling the market further. Thus, the COVID-19 pandemic has positively impacted the European biologics market during the pandemic period. 

The manufacturers have performed biologics safety testing to detect viruses, Mycoplasma, and bacterial toxins. As a result, the market has experienced specific growth. According to World Health Organization (WHO), by 2020, chronic diseases would develop cardiovascular disease (CVD) cause 3.9 million deaths in Europe Cancer, autoimmune diseases, and over 1.8 million deaths in the EU overall Europe biologics market.

 For example, the National Research Council of Canada and CanSino Biologics, based in China, partnered in May 2020 on the clinical production of a COVID-19 vaccine in Canada. In addition, Ad5-nCoV is an adenovirus Type 5 vector-based vaccine currently in Phase II production in Wuhan, China. As a result, comprehensive research and development activities on biologics for the treatment of COVID-19 are expected to fuel the expansion of Europe biologics market.

This research report on the European Biologics Market has been segmented & sub-segmented into the following categories:

By Source:  

  • Microbial
  • Mammalian
  • Others

By Product:

  • Monoclonal Antibodies
  • Vaccines
  • Recombinant Proteins
  • Antisense, RNAi, & Molecular Therapy
  • Others

By Biologics Manufacturing:

  • Outsourced
  • In-house

By Disease Category:

  • Oncology
  • Infectious Diseases
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Geographically, the European biologics market is expected to rise at a rapid pace during the forecast period. The market growth of the European market is aided by the rising frequency of chronic diseases, continued research and development, and ongoing investment in biologics. In addition, the European population is growing older, with one-fifth of the population over the age of 65. Therefore, the market continued expansion of its product variety and the rising demand for biologics across Europe are credited with the increase. Furthermore, the biopharmaceutical contract manufacturing market is rising due to increased outsourcing by pharmaceutical companies in countries such as Germany, the United Kingdom, and France in the European region.

The German biologics market is expected to have the largest share in the European market during the forecast period. In the country, there has been a significant increase in the burden of lifestyle diseases. In Germany, diabetes, infectious diseases, oncology, and other diseases are rising, which is projected to fuel market growth in the coming years.

The United Kingdom biologics market is predicted to be another profitable regional market in Europe, with a solid growth rate over the projection period. Furthermore, the United Kingdom is anticipated to maintain its leadership position in the Europe biologics market over the forecast period, owing to increased biologics medicine approvals by regulatory bodies.

KEY MARKET PLAYERS:

A few notable companies operating in the European biologics market analyzed in this report are Johnson & Johnson (J&J), F Hoffmann-La Roche, Bristol-Myers Squibb, GlaxoSmithKline, AbbVie, Amgen, Sanofi, Eli Lilly and Company, Merck & Co., and Pfizer Inc

  1. Introduction

    1. Market Definition

    2. Study Deliverables

    3. Base Currency, Base Year and Forecast Periods

    4. General Study Assumptions

  2. Research Methodology

    1. Introduction

    2. Research Phases

        1. Secondary Research

        2. Primary Research

        3. Econometric Modelling

        4. Expert Validation

    3. Analysis Design

    4. Study Timeline

  3. Overview

    1. Executive Summary

    2. Key Inferences

    3. New Developments

  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

    1. Market Drivers

    2. Market Restraints

    3. Key Challenges

    4. Current Opportunities in the Market

  5. Market Segmentation

    1. By Source

      1. Microbial

      2. Mammalian

      3. Others

    2. By Product

      1. Monoclonal Antibodies

      2. Vaccines

      3. Recombinant Proteins

      4. Antisense, RNAi, & Molecular Therapy

      5. Others

    3. By Biologics Manufacturing

      1. Outsourced

      2. In-house

    4. By Disease Category

      1. Oncology

      2. Infectious Diseases

      3. Immunological Disorders

      4. Cardiovascular Disorders

      5. Hematological Disorders

      6. Others

  6. Geographical Analysis

    1. Introduction    

      1. Regional Trends   

      2. Impact Analysis    

      3. Y-o-Y Growth Analysis        

        1. By Geographical Area

        2. By Product

        3. By Technology

        4. By Application

        5. By End-User

      4. Market Attractiveness Analysis      

        1. By Geographical Area

        2. By Product

        3. By Technology

        4. By Application

        5. By End-User

      5.      Market Share Analysis   

        1. By Geographical Area

        2. By Product

        3. By Technology

        4. By Application

        5. By End-User

    2. Europe

      1. Introduction

      2. UK

      3. France

      4. Spain

      5. Germany

      6. Italy

  7. Strategic Analysis

    1. PESTLE analysis

      1. Political

      2. Economic

      3. Social

      4. Technological

      5. Legal

      6. Environmental

    2. Porter’s Five analysis

      1. Bargaining Power of Suppliers

      2. Bargaining Power of Consumers

      3. Threat of New Entrants

      4. Threat of Substitute Products and Services

      5. Competitive Rivalry within the Industry

  8. Market Leaders' Analysis

    1. Johnson & Johnson (J&J)

      1. Overview

      2. Product Analysis

      3. Strategic Evaluation and Operations

      4. Financial analysis

      5. Legal issues

      6. Recent Developments

      7. SWOT analysis

      8. Analyst View

    2. F Hoffmann-La Roche

    3. Bristol-Myers Squibb

    4. GlaxoSmithKline

    5. AbbVie

    6. Amgen

    7. Sanofi

    8. Eli Lilly and Company

    9. Merck & Co.

    10. Pfizer

  9. Competitive Landscape

    1. Market share analysis

    2. Merger and Acquisition Analysis

    3. Agreements, Collaborations and Joint Ventures

    4. New Product Launches

  10. Market Outlook and Investment Opportunities

  11. Appendix

    1. List of Tables

    2. List of Figures  

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identifying the regions that are still untapped.

  • The segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis lists out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies.

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.

  1. Europe Biologics Market, By Source, From 2021 to 2026 (USD Million)

  2. Europe Microbial Market, By Region, From 2021 to 2026 (USD Million)

  3. Europe Mammalian Market, By Region, From 2021 to 2026 (USD Million)

  4. Europe Others Market, By Region, From 2021 to 2026 (USD Million)

  5. Europe Biologics Market, By Product, From 2021 to 2026 (USD Million)

  6. Europe Monoclonal Antibodies Market, By Region, From 2021 to 2026 (USD Million)

  7. Europe Vaccines Market, By Region, From 2021 to 2026 (USD Million)

  8. Europe Recombinant Proteins Market, By Region, From 2021 to 2026 (USD Million)

  9. Europe Antisense, RNAi, & Molecular Therapy Market, By Region, From 2021 to 2026 (USD Million)

  10. Europe Others Market, By Region, From 2021 to 2026 (USD Million)

  11. Europe Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)

  12. Europe Outsourced Market, By Region, From 2021 to 2026 (USD Million)

  13. Europe In-house Market, By Region, From 2021 to 2026 (USD Million)

  14. Europe Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)

  15. Europe Oncology Market, By Region, From 2021 to 2026 (USD Million)

  16. Europe Infectious Diseases Market, By Region, From 2021 to 2026 (USD Million)

  17. Europe Immunological Disorders Market, By Region, From 2021 to 2026 (USD Million)

  18. Europe Cardiovascular Disorders Market, By Region, From 2021 to 2026 (USD Million)

  19. Europe Hematological Disorders Market, By Region, From 2021 to 2026 (USD Million)

  20. Europe Others Market, By Region, From 2021 to 2026 (USD Million)

  21. U.K. Biologics Market, By Source, From 2021 to 2026 (USD Million)

  22. U.K. Biologics Market, By Product, From 2021 to 2026 (USD Million)

  23. U.K. Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)

  24. U.K. Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)

  25. Germany Biologics Market, By Source, From 2021 to 2026 (USD Million)

  26. Germany Biologics Market, By Product, From 2021 to 2026 (USD Million)

  27. Germany Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)

  28. Germany Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)

  29. France Biologics Market, By Source, From 2021 to 2026 (USD Million)

  30. France Biologics Market, By Product, From 2021 to 2026 (USD Million)

  31. France Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)

  32. France Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)

  33. Italy Biologics Market, By Source, From 2021 to 2026 (USD Million)

  34. Italy Biologics Market, By Product, From 2021 to 2026 (USD Million)

  35. Italy Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)

  36. Italy Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)

  37. Spain Biologics Market, By Source, From 2021 to 2026 (USD Million)

  38. Spain Biologics Market, By Product, From 2021 to 2026 (USD Million)

  39. Spain Biologics Market, By Biologics Manufacturing, From 2021 to 2026 (USD Million)

  40. Spain Biologics Market, By Disease Category, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample